SS-31 vs MOTS-c: Research Comparison
A Side-By-Side Research Comparison Of SS-31 And MOTS-c - two mitochondrial-targeted peptides in cellular-energy research. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| SS-31 | MOTS-c | |
|---|---|---|
| Category | Anti-Aging & Longevity | Weight Loss & Metabolism |
| Compound Class | Mitochondria-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2); cardiolipin-targeting | Mitochondrial-derived peptide (MDP) encoded within 12S rRNA of mitochondrial genome |
| Evidence Tier | Approved Drug | Research Compound |
| Molecular Target | Cardiolipin on inner mitochondrial membrane; scavenges mitochondrial ROS; stabilizes cristae architecture; restores respiratory chain efficiency | AMPK activation; folate-methionine cycle; AICAR-independent AMPK signaling; nuclear translocation for gene expression regulation |
| Molecular Weight | 639.79 Da | 2174.6 Da |
| Amino Acid Sequence | D-Arg-Dmt-Lys-Phe-NH2 | MRWQEMGYIFYPRKLR |
| CAS Number | 736992-21-5 | 1627580-64-6 |
| Half-Life | ~4 hours | ~30 minutes |
| Studied For | Primary mitochondrial disease, Barth syndrome (cardiolipin deficiency), Heart failure / ischemia-reperfusion injury, Dry AMD (age-related macular degeneration) | Metabolic homeostasis, Insulin resistance / obesity, Exercise-mimetic research, AMPK activation |
About SS-31
A mitochondria-protecting peptide newly approved for the rare Barth syndrome and studied broadly for mitochondrial and heart conditions.
Read The Full SS-31 MonographAbout MOTS-c
A mitochondrial exercise-mimetic peptide; banned in sport since 2024, mostly preclinical.
Read The Full MOTS-c MonographKey Differences
- SS-31 is categorized under Anti-Aging & Longevity, while MOTS-c falls under Weight Loss & Metabolism.
- Evidence tier differs: SS-31 is classified as Approved Drug; MOTS-c is classified as Research Compound.
- Reported half-life differs: SS-31 at ~4 hours versus MOTS-c at ~30 minutes.
- Primary molecular target differs: SS-31 acts on Cardiolipin on inner mitochondrial membrane; scavenges mitochondrial ROS; stabilizes cristae architecture; restores respiratory chain efficiency; MOTS-c acts on AMPK activation; folate-methionine cycle; AICAR-independent AMPK signaling; nuclear translocation for gene expression regulation.
Continue Researching
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.